Demonstrated Safety Profile in DR
The most common adverse reactions (≥5%) reported in patients receiving EYLEA were conjunctival hemorrhage, eye pain,
cataract, vitreous detachment, vitreous floaters, and intraocular pressure
increased.
1
VISTA and VIVID: Most common
adverse reactions (≥1%)1
1 / 3
2 / 3
3 / 3
3 / 3
Less common adverse reactions reported in <1% of the patients treated with EYLEA were
hypersensitivity, retinal detachment, retinal tear, corneal edema, and injection site hemorrhage.1
VISTA and VIVID long-term safety: Most common adverse reactions2
1 / 3
2 / 3
DR phase 3 PANORAMA safety
- Safety data observed in 269 patients with NPDR through Year 1 (Week 52) in the PANORAMA trial were consistent with those seen in the
phase 3 VIVID and VISTA trials1 - No new safety signals were identified through Year 2 in the PANORAMA trial compared with the known safety profile of EYLEA in the DR population3
NPDR, nonproliferative diabetic retinopathy; SAE, serious adverse event.
